- Home
- ICON vs THAR Comparison
ICON vs THAR Comparison
Compare ICON & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- THAR
- Stock Information
- Founded
- ICON 2023
- THAR 2017
- Country
- ICON Greece
- THAR United States
- Employees
- ICON N/A
- THAR N/A
- Industry
- ICON
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- THAR Health Care
- Exchange
- ICON Nasdaq
- THAR Nasdaq
- Market Cap
- ICON 3.9M
- THAR 3.3M
- IPO Year
- ICON 2024
- THAR 2022
- Fundamental
- Price
- ICON $2.31
- THAR $1.82
- Analyst Decision
- ICON Strong Buy
- THAR Strong Buy
- Analyst Count
- ICON 1
- THAR 1
- Target Price
- ICON $4.50
- THAR $17.00
- AVG Volume (30 Days)
- ICON 3.3M
- THAR 41.7K
- Earning Date
- ICON 04-23-2025
- THAR 08-08-2025
- Dividend Yield
- ICON 100.00%
- THAR N/A
- EPS Growth
- ICON N/A
- THAR N/A
- EPS
- ICON N/A
- THAR N/A
- Revenue
- ICON $5,309,000.00
- THAR N/A
- Revenue This Year
- ICON $51.78
- THAR N/A
- Revenue Next Year
- ICON $51.90
- THAR N/A
- P/E Ratio
- ICON N/A
- THAR N/A
- Revenue Growth
- ICON 18.61
- THAR N/A
- 52 Week Low
- ICON $1.60
- THAR $0.95
- 52 Week High
- ICON $154.00
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- THAR 64.36
- Support Level
- ICON N/A
- THAR $1.30
- Resistance Level
- ICON N/A
- THAR $1.46
- Average True Range (ATR)
- ICON 0.00
- THAR 0.14
- MACD
- ICON 0.00
- THAR 0.02
- Stochastic Oscillator
- ICON 0.00
- THAR 96.17
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.